Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients

1. Caballero-Velázquez, T.
2. López-Corral, L.
3. Encinas, C.
4. Castilla-Llorente, C.
5. Martino, R.
6. Rosiñol, L.
7. Sampol, A.
8. Caballero, D.
9. Serrano, D.
10. Heras, I.
11. San Miguel, J.
12. Pérez-Simón, J.A.